The natural history of chronic hepatitis B
- PMID: 17958636
- DOI: 10.1111/j.1365-2893.2007.00909.x
The natural history of chronic hepatitis B
Abstract
The natural history of chronic hepatitis B is dependent on the age of acquiring the hepatitis B infection. Those who are infected at adolescence or adulthood (including most of the Caucasians) tend to have stable disease after hepatitis B e antigen seroconversion with normal serum alanine aminotransaminase (ALT) and hepatitis B virus (HBV) DNA levels <10(5) copies/mL (20 000 IU/mL). In contrast, those who are infected at birth or early childhood (including the majority of the world's hepatitis B carriers, i.e. Asians) have a prolonged immune tolerance phase followed by a prolonged immune clearance phase. A proportion of these patients have progressive disease after HBeAg seroconversion with HBV DNA <10(4) copies/mL (<2000 IU/mL) and ALT between 0.5 and 2x upper limit of normal. Core promoter mutations may play a part in the development of cirrhosis-related complications. However, continuing viral replication, even at a relatively low level of <10(4) copies/mL (<2000 IU/mL), is probably the most important factor for the development of complications.
Similar articles
-
Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.J Viral Hepat. 2007 Mar;14(3):147-52. doi: 10.1111/j.1365-2893.2006.00810.x. J Viral Hepat. 2007. PMID: 17305879 Review.
-
Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.J Biomed Sci. 2008 Mar;15(2):137-45. doi: 10.1007/s11373-007-9225-8. Epub 2007 Dec 5. J Biomed Sci. 2008. PMID: 18058038 Review.
-
Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.Gastroenterology. 2009 Feb;136(2):505-12. doi: 10.1053/j.gastro.2008.10.089. Epub 2008 Nov 27. Gastroenterology. 2009. PMID: 19101558
-
Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.Antivir Ther. 2009;14(5):679-85. Antivir Ther. 2009. PMID: 19704171 Clinical Trial.
-
Low frequency of precore mutants in anti-hepatitis B e antigen positive subjects with chronic hepatitis B virus infection in Chennai, Southern India.J Microbiol Biotechnol. 2008 Oct;18(10):1722-8. J Microbiol Biotechnol. 2008. PMID: 18955826
Cited by
-
Hepatitis B precore protein: pathogenic potential and therapeutic promise.Yonsei Med J. 2012 Sep;53(5):875-85. doi: 10.3349/ymj.2012.53.5.875. Yonsei Med J. 2012. PMID: 22869468 Free PMC article. Review.
-
High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B.PLoS One. 2011;6(7):e21698. doi: 10.1371/journal.pone.0021698. Epub 2011 Jul 7. PLoS One. 2011. PMID: 21750724 Free PMC article.
-
Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.Infect Immun. 2008 Sep;76(9):4071-8. doi: 10.1128/IAI.00401-08. Epub 2008 Jun 16. Infect Immun. 2008. PMID: 18559427 Free PMC article.
-
Potential mechanisms of hepatitis B virus induced liver injury.World J Gastroenterol. 2014 Sep 21;20(35):12462-72. doi: 10.3748/wjg.v20.i35.12462. World J Gastroenterol. 2014. PMID: 25253946 Free PMC article. Review.
-
Comparison of long-term immunogenicity (23 years) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children.Hum Vaccin Immunother. 2012 Aug;8(8):1071-6. doi: 10.4161/hv.20656. Epub 2012 Aug 1. Hum Vaccin Immunother. 2012. PMID: 22854666 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources